# MediWound

## Next-Generation Enzymatic Therapeutics For Non-Surgical Tissue Repair

### Global Partnerships

Mölnlycke · BSV · MIMEDX · KAKEN · VERICEL · BARDA · solventum · IPM

### Validated Enzymatic Technology Platform

### Solid Balance Sheet

- $46M cash (as of Sept 30, 2024)
- 2024 expected revenues $20M
- 3x Demand to Production Capacity
- $115M+ BARDA funding (to date)
- $15M+ DoD funding (to date)
- €16M+ EIC funding
- $25M Strategic PIPE Financing

### EscharEx®


**Next-Generation Enzymatic Debridement Drug Candidate for Chronic Wounds**

Rapid, effective, safe debridement for two indications:

- Venous Leg Ulcesr (VLU) and Diabetic Foot Ulcers (DFU)

Easy to use topical application for all patient settings

Debrides chronic ulcers within 4-8 applications

Promotes granulation tissue and reduces bacteria & biofilm

Demonstrated superiority over SANTYL®

Targets a $2B market

De-risked program: Validated technology; successful Phase 2 trials

- Phase III VLU planned for Q4 2024
- Phase II/III DFU preparations currently underway

R&D collaborations with Mölnlycke, Solventum, MIMEDX

### NexoBrid®


**Disruptive Therapy for Burn Care**
**FDA, EMA approved**

Poised to replace standard of care in eschar removal for severe burns

Significantly reduces need for surgery and reduces blood loss

Topical application at bedside

Preserves viable tissue and improves patient outcomes (scar quality and function)

Clinically and commercially validated

c-GMP sterile manufacturing facility to support global demand

Approved in 40+ countries; 13K+ patients treated to-date